The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Radioactive Diagnostic Drugs Market Research Report 2025
Synopsis
The global Radioactive Diagnostic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Radioactive Diagnostic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Radioactive Diagnostic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Radioactive Diagnostic Drugs in Oncology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Radioactive Diagnostic Drugs include Curium, Medi-Radiopharma, Jubilant Radiopharma, Telix, Mallinckrodt, Cardinal Health, Bayer AG, GE Healthcare and Mallinckrodt Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Radioactive Diagnostic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioactive Diagnostic Drugs.
Report Scope
The Radioactive Diagnostic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radioactive Diagnostic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radioactive Diagnostic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Curium
Medi-Radiopharma
Jubilant Radiopharma
Telix
Mallinckrodt
Cardinal Health
Bayer AG
GE Healthcare
Mallinckrodt Pharmaceuticals
Bracco Group
Segment by Type
Single Photon Drugs
Positron Drugs
Blood Perfusion Drugs
Metabolizing Drugs
Receptor Binding Drugs
Others
Segment by Application
Oncology
Cardiology
Neuroscience
Thyroid
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radioactive Diagnostic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Radioactive Diagnostic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Radioactive Diagnostic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Radioactive Diagnostic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Radioactive Diagnostic Drugs in Oncology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Radioactive Diagnostic Drugs include Curium, Medi-Radiopharma, Jubilant Radiopharma, Telix, Mallinckrodt, Cardinal Health, Bayer AG, GE Healthcare and Mallinckrodt Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Radioactive Diagnostic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioactive Diagnostic Drugs.
Report Scope
The Radioactive Diagnostic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radioactive Diagnostic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radioactive Diagnostic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Curium
Medi-Radiopharma
Jubilant Radiopharma
Telix
Mallinckrodt
Cardinal Health
Bayer AG
GE Healthcare
Mallinckrodt Pharmaceuticals
Bracco Group
Segment by Type
Single Photon Drugs
Positron Drugs
Blood Perfusion Drugs
Metabolizing Drugs
Receptor Binding Drugs
Others
Segment by Application
Oncology
Cardiology
Neuroscience
Thyroid
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radioactive Diagnostic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radioactive Diagnostic Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Single Photon Drugs
1.2.3 Positron Drugs
1.2.4 Blood Perfusion Drugs
1.2.5 Metabolizing Drugs
1.2.6 Receptor Binding Drugs
1.2.7 Others
1.3 Market by Application
1.3.1 Global Radioactive Diagnostic Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neuroscience
1.3.5 Thyroid
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radioactive Diagnostic Drugs Market Perspective (2019-2030)
2.2 Radioactive Diagnostic Drugs Growth Trends by Region
2.2.1 Global Radioactive Diagnostic Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Radioactive Diagnostic Drugs Historic Market Size by Region (2019-2024)
2.2.3 Radioactive Diagnostic Drugs Forecasted Market Size by Region (2025-2030)
2.3 Radioactive Diagnostic Drugs Market Dynamics
2.3.1 Radioactive Diagnostic Drugs Industry Trends
2.3.2 Radioactive Diagnostic Drugs Market Drivers
2.3.3 Radioactive Diagnostic Drugs Market Challenges
2.3.4 Radioactive Diagnostic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radioactive Diagnostic Drugs Players by Revenue
3.1.1 Global Top Radioactive Diagnostic Drugs Players by Revenue (2019-2024)
3.1.2 Global Radioactive Diagnostic Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Radioactive Diagnostic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radioactive Diagnostic Drugs Revenue
3.4 Global Radioactive Diagnostic Drugs Market Concentration Ratio
3.4.1 Global Radioactive Diagnostic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioactive Diagnostic Drugs Revenue in 2023
3.5 Radioactive Diagnostic Drugs Key Players Head office and Area Served
3.6 Key Players Radioactive Diagnostic Drugs Product Solution and Service
3.7 Date of Enter into Radioactive Diagnostic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioactive Diagnostic Drugs Breakdown Data by Type
4.1 Global Radioactive Diagnostic Drugs Historic Market Size by Type (2019-2024)
4.2 Global Radioactive Diagnostic Drugs Forecasted Market Size by Type (2025-2030)
5 Radioactive Diagnostic Drugs Breakdown Data by Application
5.1 Global Radioactive Diagnostic Drugs Historic Market Size by Application (2019-2024)
5.2 Global Radioactive Diagnostic Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Radioactive Diagnostic Drugs Market Size (2019-2030)
6.2 North America Radioactive Diagnostic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Radioactive Diagnostic Drugs Market Size by Country (2019-2024)
6.4 North America Radioactive Diagnostic Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radioactive Diagnostic Drugs Market Size (2019-2030)
7.2 Europe Radioactive Diagnostic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Radioactive Diagnostic Drugs Market Size by Country (2019-2024)
7.4 Europe Radioactive Diagnostic Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radioactive Diagnostic Drugs Market Size (2019-2030)
8.2 Asia-Pacific Radioactive Diagnostic Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Radioactive Diagnostic Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Radioactive Diagnostic Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radioactive Diagnostic Drugs Market Size (2019-2030)
9.2 Latin America Radioactive Diagnostic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Radioactive Diagnostic Drugs Market Size by Country (2019-2024)
9.4 Latin America Radioactive Diagnostic Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radioactive Diagnostic Drugs Market Size (2019-2030)
10.2 Middle East & Africa Radioactive Diagnostic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Radioactive Diagnostic Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Radioactive Diagnostic Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Curium
11.1.1 Curium Company Detail
11.1.2 Curium Business Overview
11.1.3 Curium Radioactive Diagnostic Drugs Introduction
11.1.4 Curium Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.1.5 Curium Recent Development
11.2 Medi-Radiopharma
11.2.1 Medi-Radiopharma Company Detail
11.2.2 Medi-Radiopharma Business Overview
11.2.3 Medi-Radiopharma Radioactive Diagnostic Drugs Introduction
11.2.4 Medi-Radiopharma Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.2.5 Medi-Radiopharma Recent Development
11.3 Jubilant Radiopharma
11.3.1 Jubilant Radiopharma Company Detail
11.3.2 Jubilant Radiopharma Business Overview
11.3.3 Jubilant Radiopharma Radioactive Diagnostic Drugs Introduction
11.3.4 Jubilant Radiopharma Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.3.5 Jubilant Radiopharma Recent Development
11.4 Telix
11.4.1 Telix Company Detail
11.4.2 Telix Business Overview
11.4.3 Telix Radioactive Diagnostic Drugs Introduction
11.4.4 Telix Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.4.5 Telix Recent Development
11.5 Mallinckrodt
11.5.1 Mallinckrodt Company Detail
11.5.2 Mallinckrodt Business Overview
11.5.3 Mallinckrodt Radioactive Diagnostic Drugs Introduction
11.5.4 Mallinckrodt Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.5.5 Mallinckrodt Recent Development
11.6 Cardinal Health
11.6.1 Cardinal Health Company Detail
11.6.2 Cardinal Health Business Overview
11.6.3 Cardinal Health Radioactive Diagnostic Drugs Introduction
11.6.4 Cardinal Health Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.6.5 Cardinal Health Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Detail
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Radioactive Diagnostic Drugs Introduction
11.7.4 Bayer AG Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.7.5 Bayer AG Recent Development
11.8 GE Healthcare
11.8.1 GE Healthcare Company Detail
11.8.2 GE Healthcare Business Overview
11.8.3 GE Healthcare Radioactive Diagnostic Drugs Introduction
11.8.4 GE Healthcare Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.8.5 GE Healthcare Recent Development
11.9 Mallinckrodt Pharmaceuticals
11.9.1 Mallinckrodt Pharmaceuticals Company Detail
11.9.2 Mallinckrodt Pharmaceuticals Business Overview
11.9.3 Mallinckrodt Pharmaceuticals Radioactive Diagnostic Drugs Introduction
11.9.4 Mallinckrodt Pharmaceuticals Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.9.5 Mallinckrodt Pharmaceuticals Recent Development
11.10 Bracco Group
11.10.1 Bracco Group Company Detail
11.10.2 Bracco Group Business Overview
11.10.3 Bracco Group Radioactive Diagnostic Drugs Introduction
11.10.4 Bracco Group Revenue in Radioactive Diagnostic Drugs Business (2019-2024)
11.10.5 Bracco Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
